TriangleN-803 + Nivolumab/Ipilimumab (NCT07355205)
N-803 + Nivolumab/Ipilimumab trial for Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer (NCT07355205). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with stage four or recurrent non-small cell lung cancer who have not had treatment for advanced disease.
The idea: give two immunotherapy antibodies, nivolumab and ipilimumab, by vein, and add N-803, a shot under the skin. N-803 is a form of interleukin 15, a signal that helps immune cells grow and stay active. The hope is that it boosts the other two drugs.
The study looks at safety and how well it works.
This phase 1 and 2 study plans 26 patients. At Washington University School of Medicine in St. Louis, Giordano Cittolin Santos leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.